Physician profile
Richard Kass
NPI 1730103763
$3,016.69
in general payments reported to CMS, 2019-2025
23 companies · $30.62 in 2025
The $30.62 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $605 · 2021: $771 · 2022: $413 · 2023: $425 · 2024: $279 · 2025: $30.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $764.63 | 2019-2024 | Avvigo Guidance System, Watchman Access System |
| Janssen Pharmaceuticals, INC | $496.27 | 2019-2022 | |
| Pfizer INC. | $327.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $231.71 | 2020-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $179.72 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $149.99 | 2020-2022 | |
| Edwards Lifesciences Corporation | $119.20 | 2021-2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $118.20 | 2019-2021 | |
| Amgen INC. | $114.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.52 | 2019-2023 | |
| Akcea Therapeutics, INC. | $83.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $64.31 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $54.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.92 | 2019 | |
| Biosense Webster, INC. | $41.57 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $18.98 | 2024 | (5044) Mcot |
| Althera Pharmaceuticals LLC | $18.52 | 2021 | |
| Esperion Therapeutics, INC. | $17.38 | 2021 | |
| Bausch Health US, LLC | $16.37 | 2022 | |
| Atricure, INC. | $15.97 | 2019 | |
| Almatica Pharma LLC | $15.86 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Lilly USA, LLC | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.